e-learning
resources
Paris 2018
Wednesday, 19.09.2018
Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Andrographolide inhibits the activation of NLRP3 inflammasome in patients with COPD
W. Xiao (Chengdu, China), J. Fu (Chengdu, China), S. Wang (Chengdu, China), Y. Wang (Chengdu, China), T. Miao (Chengdu, China), B. Mao (Chengdu, China)
Source:
International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control
Session:
Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control
Session type:
Poster Discussion
Number:
5246
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Xiao (Chengdu, China), J. Fu (Chengdu, China), S. Wang (Chengdu, China), Y. Wang (Chengdu, China), T. Miao (Chengdu, China), B. Mao (Chengdu, China). Andrographolide inhibits the activation of NLRP3 inflammasome in patients with COPD. 5246
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Effusions related to TB
Laboratory diagnosis of tuberculosis
Related content which might interest you:
The activation of NLRP3 inflammasome pathway in COPD is limited in local airways
Source: International Congress 2018 – Disease exacerbations from a molecular point of view
Year: 2018
Cigarette smoke extract inhibits the NLRP3 inflammasome in human macrophages and impairs cell metabolism via NLRP3-independent activation of Caspase-1
Source: International Congress 2019 – Effects of environmental exposures in lung pathology and the underlying mechanisms
Year: 2019
Statins worse pulmonary fibrosis through enhancing NLRP3 inflammasome activation
Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD
Year: 2012
Tetracycline alleviates acute lung injury by inhibition of NLRP3 inflammasome
Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure
Year: 2019
Activation of the inflammasome pathway during exacerbations of COPD
Source: Annual Congress 2011 - Recent developments in COPD
Year: 2011
NLRP3 inflammasome conjugates with mitochondria in LPS-induced acute lung injury
Source: Virtual Congress 2020 – Cellular stress in respiratory diseases
Year: 2020
A role for the inflammasome effector caspase-1 in hypoxia-induced pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017
Elevated expression of the NLRP3 inflammasome in neutrophilic asthma
Source: Eur Respir J 2014; 43: 1067-1076
Year: 2014
Caspase-1 pathway in COPD
Source: Annual Congress 2010 - COPD and asthma: models and human studies
Year: 2010
The NLRP3 inflammasome pathway is activated in sarcoidosis and involved in granuloma formation
Source: Eur Respir J, 55 (3) 1900119; 10.1183/13993003.00119-2019
Year: 2020
In addition to mTOR and JAK/STAT, NLRP3 inflammasome is another key pathway activated in sarcoidosis
Source: Eur Respir J, 55 (3) 2000149; 10.1183/13993003.00149-2020
Year: 2020
Late Breaking Abstract - 17-oxo-DHA inhibits the NLRP3 inflammasome downstream of mitochondrial ROS and ERK pathway
Source: International Congress 2017 – New Mechanistic Findings in COPD
Year: 2017
Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Activation of IL-32 pathway in COPD
Source: Annual Congress 2008 - Cell biology of asthma and COPD
Year: 2008
NLRP3 inflammasome is activated via phosphoinositide 3-kinase δ pathway in Aspergillus fumigatus-induced allergic airway inflammation
Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions
Year: 2015
Decreased PTEN amplifies PI3K signaling and enhances pro-inflammatory cytokine release in COPD
Source: International Congress 2016 – Studies in airway cell biology
Year: 2016
Activation of NLRP3 inflammasome is regulated by mitochondrial ROS via PI3K-HIF-VEGF pathway in acute lung injury
Source: International Congress 2015 – Novel insights into the pathobiology of acute lung injury
Year: 2015
Role of NLRP3 inflammasome and ATP in S100A12-induced MUC5AC production in airway epithelial cells
Source: International Congress 2018 – New kids on the block: novel molecular pathways and therapeutic targets in chronic lung diseases
Year: 2018
NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung
Source: Eur Respir J 2016; 47: 910-918
Year: 2016
Roflumilast potently inhibits CXCL1 mediated neutrophil migration in COPD patients
Source: Annual Congress 2011 - COPD: clinical studies and animal cell models
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept